In vitro and in vivo characterization of JNJ-31020028 (N-(4-{4-[2- (diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl) -2-pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the neuropeptide y Y2 receptor

Psychopharmacology

Volumn 208, Issue 2, 2010, Pages 265-277

  Shoblock, James R ^a   Welty, Natalie ^a   Nepomuceno, Diane ^a   Lord, Brian ^a   Aluisio, Leah ^a   Fraser, Ian ^a   Motley, S Timothy ^a   Sutton, Steve W ^a   Morton, Kirsten ^a   Galici, Ruggero ^a   Atack, John R ^a   Dvorak, Lisa ^a   Swanson, Devin M ^a   Carruthers, Nicholas I ^a   Dvorak, Curt ^a   Lovenberg, Timothy W ^a   Bonaventure, Pascal ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Anxiety; Hypothalamus; Microdialysis; Neuropeptide Y Y2 receptor; Norepinephrine; Stress induced anorexia

Indexed keywords

CLOBAZAM; CORTICOSTERONE; DIAZEPAM; JNJ 31020028; LORAZEPAM; N (1 ACETYL 2,3 DIHYDRO 1H INDOL 6 YL) 3 (3 CYANOPHENYL) N [1 (2 CYCLOPENTYLETHYL) 4 PIPERIDINYL]ACRYLAMIDE; N (1 ACETYL 2,3 DIHYDRO 1H INDOL 6 YL) 3 (3 CYANOPHENYL) N [1 (2 CYCLOPENTYLETHYL)PIPERIDIN 4YL]ACRYLAMIDE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ(B,E)AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N [2 [1,2 DIHYDRO 3,5(4H) DIOXO 1,2 DIPHENYL 1,2,4 TRIAZOL 4 YL]ETHYL] N2 [[1 [2 [4 [5,11 DIHYDRO 6(6H) OXODIBENZ[B,E]AZEPIN 11 YL] 1 PIPERAZINYL] 2 OXOETHYL]CYCLOPENTYL]ACETYL]ARGININAMIDE; N [4 [4 [2 (DIETHYLAMINO) 2 OXO 1 PHENYLETHYL]PIPERAZIN 1 YL] 3 FLUOROPHENYL] 2 PYRIDIN 3 YLBENZAMIDE; NALPHA (DIPHENYLACETYL) N (4 HYDROXYBENZYL) DEXTRO ARGININAMIDE; NEUROPEPTIDE Y RECEPTOR ANTAGONIST; NEUROPEPTIDE Y1 RECEPTOR; NEUROPEPTIDE Y2 RECEPTOR; NEUROPEPTIDE Y5 RECEPTOR; NORADRENALIN; UNCLASSIFIED DRUG; ANXIOLYTIC AGENT; BENZAMIDE DERIVATIVE; CALCIUM; JNJ-31020028; NEUROPEPTIDE Y RECEPTOR; PEPTIDE YY; PIPERAZINE DERIVATIVE;

ANIMAL EXPERIMENT; ANOREXIA; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BINDING AFFINITY; BINDING SITE; CALCIUM MOBILIZATION; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FOOD INTAKE; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MAZE TEST; MICRODIALYSIS; NONHUMAN; NORADRENALIN RELEASE; PRIORITY JOURNAL; PROTEIN BINDING; RAT; STRESS; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANQUILIZING ACTIVITY; ANIMAL; AUTORADIOGRAPHY; BINDING COMPETITION; BLOOD; CHO CELL; CRICETULUS; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; EATING; FEEDING BEHAVIOR; GENETIC TRANSFECTION; GENETICS; HAMSTER; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MOUSE; ORAL DRUG ADMINISTRATION; PERMEABILITY; PSYCHOLOGICAL ASPECT; SPRAGUE DAWLEY RAT; SUBCUTANEOUS DRUG ADMINISTRATION; VAS DEFERENS; WISTAR RAT;

ADMINISTRATION, ORAL; ANIMALS; ANOREXIA; ANTI-ANXIETY AGENTS; ANXIETY; AUTORADIOGRAPHY; BENZAMIDES; BINDING, COMPETITIVE; CALCIUM; CHO CELLS; CORTICOSTERONE; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; FEEDING BEHAVIOR; HIPPOCAMPUS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MALE; MICE; MICRODIALYSIS; NOREPINEPHRINE; PEPTIDE YY; PERMEABILITY; PIPERAZINES; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; RECEPTORS, NEUROPEPTIDE Y; TRANSFECTION; VAS DEFERENS;

EID: 77449156694     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-009-1726-x     Document Type: Article

References (39)

1. CJ Andres I Antal Zimanyi MS Deshpande LG Iben K Grant-Young GK Mattson W Zhai 2003 Differentially functionalized diamines as novel ligands for the NPY2 receptor Bioorg Med Chem Lett 13 2883 2885 10.1016/S0960-894X(03)00554-7 1:CAS:528:DC%2BD3sXmvFajuro%3D 14611849
2. F Bacchi AA Mathé P Jiménez L Stasi R Arban P Gerrard L Caberlotto 2006 Anxiolytic-like effect of the selective neuropeptide Y Y2 receptor antagonist BIIE0246 in the elevated plus-maze Peptides 27 3202 3207 10.1016/j.peptides.2006.07.020 1:CAS:528:DC%2BD28Xht1Cisr7K 16959374
3. B Beck 2006 Neuropeptide Y in normal eating and in genetic and dietary-induced obesity Philos Trans R Soc Lond B Biol Sci 361 1159 1185 10.1098/rstb.2006.1855 1:CAS:528:DC%2BD28XhtVygt7fE 16874931
4. P Bonaventure D Nepomuceno C Mazur B Lord DA Rudolph JA Jablonowski NI Carruthers TW Lovenberg 2004 Characterization of N-(1-acetyl-2, 3-dihydro-1H-indol-6-yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopen tyl-ethyl)-piperidin-4yl]acrylamide (JNJ-5207787), a small molecule antagonist of the neuropeptide Y Y2 receptor J Pharmacol Exp Ther 308 1130 1137 10.1124/jpet.103.060459 1:CAS:528:DC%2BD2cXhvVWnurc%3D 14617685
5. A Brennauer S Dove A Buschauer 2004 Structure-activity relationships of nonpeptide neuropeptide Y receptor antagonists Handb Exp Pharmacol 162 505 546 1:CAS:528:DC%2BD2cXivVyhtb0%3D
6. L Caberlotto K Fuxe YL Hurd 2000 Characterization of NPY mRNA-expressing cells in the human brain: co-localization with Y2 but not Y1 mRNA in the cerebral cortex, hippocampus, amygdala, and striatum J Chem Neuroanat 20 327 337 10.1016/S0891-0618(00)00107-1 1:CAS:528:DC%2BD3MXht1Oqt7s%3D 11207429
7. Caberlotto L, Arban R, Zambello E (2007) NPY Y2 receptor knock-out mice: influence of genetic background on anxiety related behaviors. Abstract from Society for Neuroscience, Annual Meeting San Diego
8. C Carvajal Y Dumont R Quirion 2006 Neuropeptide y: role in emotion and alcohol dependence CNS Neurol Disord Drug Targets 5 181 195 10.2174/ 187152706776359592 1:CAS:528:DC%2BD28XktlCntL4%3D 16611091
9. FM Dautzenberg 2005 Stimulation of neuropeptide Y-mediated calcium responses in human SMS-KAN neuroblastoma cells endogenously expressing Y2 receptors by co-expression of chimeric G proteins Bioch Pharmacol 69 1493 1499 10.1016/j.bcp.2005.02.014 1:CAS:528:DC%2BD2MXjs1Ckurs%3D
10. H Doods W Gaida HA Wieland H Dollinger G Schnorrenberg F Esser W Engel W Eberlein K Rudolf 1999 BIIE0246: a selective and high affinity neuropeptide Y Y(2) receptor antagonist Eur J Pharmacol 384 R3 R5 10.1016/S0014-2999(99)00650-0 1:CAS:528:DyaK1MXotVOiu7k%3D 10611450
11. Y Dumont A Fournier S St-Pierre R Quirion 1996 Autoradiographic distribution of [125I]Leu31, Pro34]PYY and [125I]PYY3-36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands Synapse 22 139 158 10.1002/(SICI)1098-2396(199602)22:2<139::AID-SYN7>3.0. CO;2-E 1:CAS:528:DyaK28XovVersg%3D%3D 8787130
12. Y Dumont A Cadieux H Doods LH Pheng R Abounader E Hamel D Jacques D Regoli R Quirion 2000 BIIE0246, a potent and highly selective non-peptide neuropeptide Y Y(2) receptor antagonist Br J Pharmacol 129 1075 1088 10.1038/sj.bjp.0703162 1:CAS:528:DC%2BD3cXit1egsrw%3D 10725255
13. N Erondu I Gantz B Musser S Suryawanshi M Mallick C Addy J Cote G Bray K Fujioka H Bays P Hollander SM Sanabria-Bohorquez W Eng B Langstrom RJ Hargreaves HD Burns A Kanatani T Fukami DJ MacNeil KM Gottesdiener JM Amatruda KD Kaufman SB Heymsfield 2006 Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults Cell Metab 4 275 282 10.1016/j.cmet.2006.08.002 1:CAS:528:DC%2BD28XhtFCgtrfL 17011500
14. DR Gehlert SL Gackenheimer 1997 Differential distribution of neuropeptide Y Y1 and Y2 receptors in rat and guinea-pig brains Neuroscience 76 215 224 10.1016/S0306-4522(96)00340-5 1:CAS:528:DyaK28Xns1ajtr8%3D 8971773
15. DR Gehlert LS Beavers D Johnson SL Gackenheimer DA Schober RA Gadski 1996 Expression cloning of a human brain neuropeptide Y Y2 receptor Mol Pharmacol 49 224 228 1:CAS:528:DyaK28XhtFOgsbY%3D 8632753
16. E Grouzmann T Buclin M Martire C Cannizzaro B Dorner A Razaname M Mutter 1997 Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. Synthesis and pharmacological evaluation of a Y2 antagonist J Biol Chem 272 7699 7706 10.1074/jbc.272.12.7699 1:CAS:528:DyaK2sXitFWgtLc%3D 9065428
17. J Harro 2006 CCK and NPY as anti-anxiety treatment targets: promises, pitfalls, and strategies Amino Acids 31 215 230 10.1007/s00726-006-0334-x 1:CAS:528:DC%2BD28XhtVKjtLjL 16738800
18. M Heilig 2004 The NPY system in stress, anxiety and depression Neuropeptides 38 213 224 10.1016/j.npep.2004.05.002 1:CAS:528: DC%2BD2cXntVOjsbw%3D 15337373
19. H Herzog 2002 Hypothalamic Y2 receptors: central coordination of energy homeostasis and bone mass regulation Drug News Perspect 15 506 510 10.1358/dnp.2002.15.8.740226 1:CAS:528:DC%2BD38XpsVWjsr8%3D 12677189
20. VR Holets T Hokfelt A Rokaeus L Terenius M Goldstein 1988 Locus coeruleus neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent projections to the spinal cord, cerebral cortex and hypothalamus Neuroscience 24 893 906 10.1016/0306-4522(88)90076-0 1:CAS:528:DyaL1cXitFKqtbY%3D 2454419
21. SP Kalra MG Dube PS Kalra 1988 Continuous intraventricular infusion of neuropeptide Y evokes episodic food intake in satiated female rats: effects of adrenalectomy and cholecystokinin Peptides 9 723 728 10.1016/0196-9781(88)90112- X 1:CAS:528:DyaL1cXmtVGmurs%3D 3226950
22. A Kask L Rägo J Harro 1998 Anxiolytic-like effect of neuropeptide Y (NPY) and NPY13-36 microinjected into vicinity of locus coeruleus in rats Brain Res 788 345 348 10.1016/S0006-8993(98)00076-6 1:CAS:528:DyaK1cXhvVSisL0%3D 9555090
23. PJ King G Williams H Doods PS Widdowson 2000 Effect of a selective neuropeptide Y Y(2) receptor antagonist, BIIE0246 on neuropeptide Y release Eur J Pharmacol 396 R1 R3 10.1016/S0014-2999(00)00230-2 1:CAS:528: DC%2BD3cXjsVGnt7o%3D 10822055
24. LE Kuo JB Kitlinska JU Tilan L Li SB Baker MD Johnson EW Lee MS Burnett ST Fricke R Kvetnansky H Herzog Z Zukowska 2007 Neuropeptide Y acts directly in the periphery on fat tissue and mediates stress-induced obesity and metabolic syndrome Nat Med 13 803 811 10.1038/nm1611 1:CAS:528:DC%2BD2sXnsFWmt70%3D 17603492
25. A Lecci F Borsini G Volterra A Meli 1990 Pharmacological validation of a novel animal model of anticipatory anxiety in mice Psychopharmacology (Berl) 101 255 261 10.1007/BF02244136 1:CAS:528:DyaK3cXktlCls7s%3D
26. EW Lee DS Grant S Movafagh Z Zukowska 2003 Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice Peptides 24 99 106 10.1016/S0196-9781(02)00281-4 1:CAS:528:DC%2BD3sXptFGksA%3D%3D 12576090
27. DJ MacNeil 2007 NPY Y1 and Y5 receptor selective antagonists as anti-obesity drugs Curr Top Med Chem 7 1721 1733 10.2174/156802607782341028 1:CAS:528:DC%2BD2sXhsVOrtbvL 17979781
28. M Martire G Pistritto N Mores LF Agnati K Fuxe 1993 Region-specific inhibition of potassium-evoked [3H]noradrenaline release from rat brain synaptosomes by neuropeptide Y-(13-36). Involvement of NPY receptors of the Y2 type Eur J Pharmacol 230 231 234 10.1016/0014-2999(93)90807-T 1:CAS:528:DyaK3sXhsVSlsbs%3D 8422905
29. P Mele A Oberto M Serra MG Pisu I Floris G Biggio C Eva 2004 Increased expression of the gene for the Y1 receptor of neuropeptide Y in the amygdala and paraventricular nucleus of Y1R/LacZ transgenic mice in response to restraint stress J Neurochem 89 1471 1478 10.1111/j.1471-4159.2004.02444.x 1:CAS:528:DC%2BD2cXlsVOhur8%3D 15189350
30. E Painsipp T Wultsch ME Edelsbrunner RO Tasan N Singewald H Herzog P Holzer 2008 Reduced anxiety-like and depression-related behavior in neuropeptide Y Y4 receptor knockout mice Genes Brain Behav 7 532 542 10.1111/j.1601-183X. 2008.00389.x 1:STN:280:DC%2BD1cvosl2huw%3D%3D 18221379
31. Paxinos G, Watson C (1997) The rat brain in stereotaxic coordinates. Academic, San Diego
32. JP Redrobe Y Dumont H Herzog R Quirion 2003 Neuropeptide Y (NPY) Y2 receptors mediate behaviour in two animal models of anxiety: evidence from Y2 receptor knockout mice Behav Brain Res 141 251 255 10.1016/S0166-4328(02)00374-1 1:CAS:528:DC%2BD3sXjsVWlsrg%3D 12742262
33. JP Redrobe C Carvajal A Kask Y Dumont R Quirion 2004 Neuropeptide Y and its receptor subtypes in the central nervous system: emphasis on their role in animal models of psychiatric disorders Handb Exp Pharmacol 162 101 136 1:CAS:528:DC%2BD2cXivVyhtL8%3D
34. JP Redrobe Y Dumont H Herzog R Quirion 2004 Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing J Mol Neurosci 22 159 166 10.1385/JMN:22:3:159 1:CAS:528:DC%2BD2cXivVSlt7o%3D 14997009
35. R Rimondini A Thorsell M Heilig 2005 Suppression of ethanol self-administration by the neuropeptide Y (NPY) Y2 receptor antagonist BIIE0246: evidence for sensitization in rats with a history of dependence Neurosci Lett 375 129 133 10.1016/j.neulet.2004.10.084 1:CAS:528:DC%2BD2MXmvF2htQ%3D%3D 15670655
36. Seierstad M, Bonaventure P, Dvorak L, Lord B, Miller KL, Motley ST, Nepomuceno D, Chai W, Dvorak CA, Jablonowski JA, Rudolph DA, Shah CR, Swanson DM, Wong VD, Axe FU, Lovenberg TW, Carruthers NI (2007) Small-molecule Y2 receptor antagonists: identification of a novel and potent series using pharmacophore-based virtual screening. Abstracts of Papers, 234th ACS National Meeting, Boston, MA, USA, August 19-23, 2007
37. TE Thiele P Naveilhan P Ernfors 2004 Assessment of ethanol consumption and water drinking by NPY Y2 receptor knockout mice Peptides 25 975 983 10.1016/j.peptides.2004.03.009 1:CAS:528:DC%2BD2cXltVGisb8%3D 15203244
38. A Tschenett N Singewald M Carli C Balducci P Salchner A Vezzani H Herzog G Sperk 2003 Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors Eur J Neurosci 18 143 148 10.1046/j.1460-9568.2003.02725.x 12859347
39. Z Zukowska-Grojec M Konarska R McCarty 1988 Differential plasma catecholamine and neuropeptide Y responses to acute stress in rats Life Sci 42 1615 1624 10.1016/0024-3205(88)90440-7 1:CAS:528:DyaL1cXhs1ahsrc%3D 3367684